Condition: Malaria,Falciparum · Sponsor: University of Oxford
This is a Phase Ib age de-escalation, dose escalation, open-label study to assess the safety and immunogenicity of the multi-stage malaria vaccine candidate R21 plus RH5.1 and/or R78C in Matrix-M in adults aged 18-35 years and children aged 5-17 months in Burkina Faso.
This description comes directly from the study's public registry record.
Naomi N Kamau · +44 (0)1865611418 · vaccinetrials@ndm.ox.ac.uk
Angela Minassian, Honorary Consultant and CI
Always discuss trial participation with your own doctor first.
| Institut de Recherche en Sciences de la Santé | Siglé, Boulkiemdé Province, Burkina Faso | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06958198